In conclusion, PITX2 DNA-methylation determined with the analytically validated therascreen PITX2 RGQ PCR assay may improve personalized breast cancer management and treatment decision in high-risk (lymph node-positive, estrogen-receptor positive, HER2-negative) breast cancer. This evidence concerns the gene PITX2 and breast carcinoma.